Ultragenyx’s Phase 3 Aspire Study Of Apazunersen Fails Primary And Key Secondary Endpoints In Angelman Syndrome
Phase 3 Aspire did not achieve the primary endpoint of change from Baseline in Bayley-4 cognitive raw score nor the key secondary endpoint of net response in Multidomain Responder Index (MDRI)NOVATO, Calif., Sept. 02,
A big test for Ultragenyx's medicine didn't show it worked as well as hoped for a rare brain condition. When a medicine test fails like this, investors watch carefully to see if the company can fix it or move forward with other ideas.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.